Phase IIa
Sponsors
Ogeda S.A, GlaxoSmithKline, Boehringer Ingelheim
Conditions
NASH (niet alcoholische steatose hepatitis)
Non alcoholic liver inflammation
Non alcoholic steatohepatitisSteinLeventhal syndromegastric/gastroesophageal cancer
head and neck cancer
or NSCLC
stage III-IV melanoma
Phase 2
A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumors
Active, not recruitingNL-OMON44080
Start: 2015-06-09Target: 40Updated: 2024-02-28
Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Polycystic Ovarian Syndrome
Active, not recruitingNL-OMON43634
Start: 2015-11-30Target: 12Updated: 2024-02-28
A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.
Active, not recruitingNL-OMON47669
Start: 2019-01-08Target: 2Updated: 2024-02-28